Welcome to our dedicated page for Mainz Biomed NV news (Ticker: MYNZ), a resource for investors and traders seeking the latest updates and insights on Mainz Biomed NV stock.
Mainz Biomed N.V. has reported developments tied to molecular genetics diagnostics for early cancer detection and a later corporate transition to the Quantum Cyber name and QUCY ticker. Its company updates have centered on ColoAlert, a non-invasive colorectal cancer screening test marketed in Europe, and PancAlert, an early-stage pancreatic cancer screening candidate using PCR-based multiplex detection of molecular-genetic biomarkers in blood and stool samples.
Recurring news themes include clinical-study and conference disclosures for colorectal and pancreatic cancer detection, commercial distribution and digital-health partnerships, financing activity, strategic updates, board governance changes, and Nasdaq ticker matters.
Mainz Biomed (NASDAQ: MYNZ) announced the appointment of Robert P. Liscouski as Chairman and plans to change its name to Quantum Cyber with a Nasdaq ticker change to QUCY beginning March 12, 2026. The permanent election and formal name change are planned for an extraordinary general meeting in April 2026.
The company said it will continue developing its U.S. pancreatic cancer screening business, evaluate a sale of its colorectal cancer screening assets, and wind down its German subsidiary. Mr. Liscouski brings government cybersecurity and quantum technology leadership experience.
Mainz Biomed (NASDAQ: MYNZ) will present clinical poster data at Digestive Disease Week 2026 in Chicago on Feb 24, 2026. The poster reports a blood-based mRNA signature for pancreatic cancer with reported 100% sensitivity and 95% specificity.
The presentation, titled “BLOOD-BASED MRNA SIGNATURE FOR DETECTION OF PANCREATIC DUCTAL ADENOCARCINOMA AND DISCRIMINATION OF INTRADUCTAL PAPILLARY MUCINOUS NEOPLASMS,” highlights the company’s discovery-study results and potential for early-stage detection.
Mainz Biomed (NASDAQ: MYNZ) announced a $6.0 million private placement and strategic refocus on its U.S. pancreatic cancer detection program on Feb 17, 2026. The financing is structured in two $3.0 million tranches, with the first tranche closed Feb 13, 2026, and the second expected before Apr 15, 2026.
The company named investor David Lazar as Chairman and said net proceeds will fund operations, address liabilities, and support asset-sale discussions for its colorectal screening business while winding down its German subsidiary.
Mainz Biomed (NASDAQ: MYNZ) will present initial verification results of a blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and differentiation of intraductal papillary mucinous neoplasms (IPMN) at the AACR 2026 Annual Meeting in San Diego, April 17–22, 2026.
The presentation covers a 30-subject verification study using a compact proprietary panel of blood-derived mRNA biomarkers combined with an AI-assisted modeling approach to distinguish PDAC from benign conditions including IPMN. Further details are slated for the online Proceedings of AACR.
Mainz Biomed (NASDAQ:MYNZ) reviewed 2025 highlights including clinical, regulatory, partnership, and funding progress for its cancer-detection programs.
Key items: launch of eAArly DETECT 2 (U.S. feasibility study, ~2,000 average-risk patients) to validate a next-generation CRC test; ColoAlert received MHRA and Swissmedic registrations and entered Swiss and South American distribution partnerships; pancreatic program licensed mRNA biomarkers from Liquid Biosciences with a discovery cohort (285 subjects; 35 pancreatic cancers) showing 95% sensitivity / 98% specificity, and a feasibility panel achieving 100% sensitivity / 95% specificity in a 30-subject cohort. State funding may cover up to 50% of pancreatic project costs.
Mainz Biomed (NASDAQ:MYNZ) announced that its DNA-based colorectal cancer home test ColoAlert was added to DoctorBox’s digital health portfolio on Dec 2, 2025. The move integrates Mainz Biomed’s diagnostics with DoctorBox’s platform and routes laboratory analysis to the European Oncology Lab led by Dr. Annette Buhlmann in St. Ingbert, Germany.
DoctorBox reports >1 million registered users and >10 million test results, and the partnership aims to expand at‑home access to DNA colorectal screening in Germany, where ~60,000 new colorectal cancer cases are diagnosed annually.
Mainz Biomed (NASDAQ:MYNZ) signed a Memorandum of Understanding with OncoVanguard8 to introduce ColoAlert, a DNA-based colorectal cancer screening test, to South America beginning with Peru. The MOU outlines core commercial, legal and regulatory terms and a go-to-market strategy for an initial territory, with a final distribution agreement targeted within weeks.
The companies identified Peru, Colombia and Ecuador as initial launch markets, where about 17,000 new colorectal cancer cases are diagnosed annually, highlighting demand for early-detection screening solutions that could raise participation and support public health goals.
Mainz Biomed (NASDAQ:MYNZ) will participate in MEDICA 2025 in Düsseldorf from November 17–20, 2025. MEDICA expects >5,000 exhibitors from 70 countries and about 80,000 visitors, offering a global platform for medical-technology networking, forums, and business development.
Mainz Biomed will showcase its flagship molecular stool-based colorectal cancer screening test ColoAlert and preview additional early-stage cancer diagnostic solutions. The company will be at the Rhineland-Pfalz joint booth in Hall 3, E92. Investors and attendees are directed to the company investor site for more information and social channels for updates.
Mainz Biomed (NASDAQ:MYNZ) announced it will attend the 38th Annual Meeting of the Gastroenterological Working Group of Rhineland-Palatinate (GARPS) from 14–15 November 2025 in Bad Kreuznach, Germany.
The company plans to present its flagship diagnostic ColoAlert® and discuss upcoming solutions for early detection of colorectal and other cancers, engage with gastroenterology key opinion leaders, and explore clinical collaborations. Attendees are invited to visit Mainz Biomed's booth to learn about offering ColoAlert to patients.
For more information, investors and physicians are directed to the company investor site at mainzbiomed.com/investors/ and the company's social channels.
Mainz Biomed (NASDAQ:MYNZ) will attend the 2025 Maxim Growth Summit in New York City on October 22-23, 2025 at The Hard Rock Hotel NYC. The company, which focuses on molecular genetics diagnostics for early cancer detection, said it will meet one-on-one with institutional investors and senior Maxim analysts during the event.
The summit features keynote speakers and roundtable sessions across sectors including biotechnology, AI, stem cell therapy and more. For the summit agenda visit www.maximgrp.com/2025-growth-summit and for investor information visit mainzbiomed.com/investors/.